Clinical Trial

Precision Radiation of Immune Checkpoint Therapy Resistant Melanoma Metastases

Study acronym: PROMMEL
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 5, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.
Summary
To evaluate tumor response, survival and adverse effects after precision radiotherapy (SBRT) in melanoma patients with ongoing PD-1 inhibitor treatment that have tumor progression.
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2021-03-08; most recent amendment 2025-03-03.
Trial Details
NCT Number NCT04793737
Lead Sponsor Karolinska University Hospital
Conditions Metastatic Melanoma
Enrollment 27 participants
Start Date 2021-03-08
Primary Completion 2025-12 (estimated)
Study Completion 2025-12 (estimated)
Updated on ClinicalTrials.gov 2025-03-05